

Paravit-CF™

(multivitamin supplement containing fat-soluble vitamins A, D₃, E and K₁)



Paravit-CF™ Peer to Peer Review

Supplementation of fat soluble vitamins A, D, E and K is a fundamental part of the nutritional management of patients with Cystic Fibrosis who have pancreatic insufficiency. As part of the polypharmacy required to treat Cystic Fibrosis, vitamin supplementation causes a significant medication burden to patients.

The vitamin regimens can be confusing and onerous with various preparations needed to meet the recommended intake, consisting of either different liquid volumes for young children or 2-3 tablets for older children. These can be hard to remember and may not be considered a priority, which can lead to difficulty in ensuring patients are receiving the correct dose of each vitamin

To overcome the concerns of confusing regimens and inaccurate dosing of vitamin preparations specific to Cystic Fibrosis have been developed, but unfortunately, there have been challenges with the prescription and supply of these novel products, with the liquid dosing of some not being ideal.

When Parapharm introduced Paravit-CF™ in liquid form, the team at Alder Hey felt this would reduce the medication burden for our patients whilst simplifying the treatment for families. As well as this,

Paravit-CF™ contains vitamin K which was previously not easily available or palatable in liquid form. The previous liquid preparation has a low Vit D content in the form of ergocalciferol. Paravit-CF™ has vitamin D in the form of cholecalciferol, which is recommended as the preferred type of vitamin D by the CF trust. Paravit-CF™ also allows a higher dose of vitamin D to be given, while the vitamin A dose remains within CF Trust recommendations.

Alder Hey Children's NHS Trust is a tertiary centre providing shared care to approximately 300 patients over North West England and North Wales. With the knowledge that Parapharm intended to manufacture a capsule form of vitamin supplement for older children, we decided to trial the use of Paravit-CF™ liquid in our younger patients. The use of Paravit-CF™ reduced the vitamin regimen from 2ml of 2 separate vitamin preparations to only 0.125ml or 0.25ml of 1 preparation depending on age.

For this reason, all our patients' families consented to the change in prescription. Although the combined preparation eases treatment, there are some disadvantages to its use, mainly the inability to adjust specific vitamin doses. However, we felt the improvement in quality of life for the family far outweighed this negative, so we proceeded with the transition. Vitamin levels are monitored in standard annual reviews for patients, so changes to dosing or the product used could be made if needed.



To facilitate the transition to Paravit-CF™, our pharmacist and I met with the representative of Parapharm. Firstly, Paravit-CF™ was added to the hospital pharmacy and the formulary for the area. This gave general practitioners (GPs) the ability to prescribe it. Parapharm ensured Paravit-CF™ was available from all local wholesalers to facilitate adequate supply to pharmacies. Despite this, there were initially some difficulties with GPs not prescribing the product and some pharmacies not willing to dispense the product or not having it in stock. To overcome this, letters were sent to GPs explaining the change and giving clear prescription requests. Letters with information for the pharmacists, regarding what to dispense and providing Parapharm representative details, were also given to parents to take to their local pharmacy. Parapharm liaised with wholesalers to increase their local stock to improve supply to pharmacies and therefore patients.

When we began using Paravit-CF™ in 2017/2018 we had some reservations regarding the dropper on the bottle of the liquid, which was suitable for the 0.25ml dose but not able to measure the under 12 month old dose of 0.125ml. I was also concerned that the dropper may not give an accurate dose of the vitamins. As the product is highly concentrated, small errors in volume could lead to patient's receiving significantly different doses to that prescribed. To overcome this we asked that all patients used a 1ml syringe and did not routinely use the dropper. Parapharm subsequently made plans to change the presentation of this bottle and provided a syringe with the product. When the capsule form became available we began prescribing this for all our older children, which reduced their vitamin regime from 6-8 tablets daily to only 1-2 tablets.

We now have over 300 patients in the network taking either the liquid or the capsule form of Paravit-CF™. Its use has been positive for patients, their families and our clinical team due to easier administration and prescription. None of the patients have difficulty in taking the product and we no longer have any prescribing or stock issues.

The monitoring of patients' vitamin levels has revealed higher vitamin D levels over the last 3 years, since using Paravit-CF™. This is likely to be due to the improved preparation and dose and therefore better patient compliance. Other factors could have affected vitamin D levels such as a warm summer, but the introduction of Paravit-CF™ seems the major factor. Some patients have developed high vitamin A levels whilst taking Paravit-CF™. This raised the concern of needing to return to single vitamin preparations. However this has not been necessary as patients have maintained good levels of vitamins A, E & D by reducing the Paravit-CF™ dose and taking additional Vitamin D as a single preparation. It is possible some of the improvement in vitamin levels is due to the use of modulator therapies and overall improved absorption for patients. Due to this, titration of vitamin doses may need to be considered in the future for patients who are seeing significant improvement in absorption from these new drugs.

We have found the use of Paravit-CF™ within our network to have a positive impact on our patients due to the reduced burden and improved knowledge of treatment. Overall the vitamin levels of our patients have improved and we have an ongoing audit to confirm this. In patients with abnormal vitamin levels, the adjustment of the dose of Paravit-CF™ with the addition of individual vitamins has been manageable and more preferable than returning to the previous products. For anyone considering changing to the use of Paravit-CF™ I would recommend early involvement with a pharmacist to ensure the product is available on the local formulary. I also advise clear communication in advance, to ensure GPs can prescribe, pharmacies can dispense and wholesalers have appropriate stock in place to facilitate a smooth transition.



ParaPharm Development Ltd.

Merlin House, Brunel Road, Theale, Reading, RG7 4AB, UK

Tel +44 (0) 118 221 0150 | Fax +44 (0) 118 221 0151

www.paravit-cf.com